CytoGenix

CytoGenix is a biopharmaceutical company at the forefront of biopharmaceutical innovations with advanced gene regulating and DNA production technologies. Founded in 1995, the company has developed a pre-clinical pipeline comprising an antimicrobial compound, DNA vaccines, and anti-herpes and anti-inflammatory topical creams. Notably, CytoGenix has engineered a cell-free process for synthesizing DNA, which is not only utilized in its own product line but also marketed to other companies. The company boasts an extensive intellectual property portfolio with 11 granted patents (1 U.S., 1 China, 9 Europe) and one additional allowance pending in India, accompanied by 11 more applications progressing globally. Furthermore, CytoGenix actively collaborates with numerous academic centers, government agencies, and biotechnology partners. As a testament to its growth and potential, the company is publicly traded under the symbol CYGX on the NASDAQ Over the Counter Bulletin Board.